- Conditions
- Pulmonary Artery Hypertension
- Interventions
- reserpine, stellate ganglion block, lidocaine
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 402
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Charleston, South Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ralinepag
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Background PAH Therapy
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- QCC374, Placebo Matching
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Secondary Pulmonary Arterial Hypertension
- Interventions
- Heart Catheterization
- Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
- Interventions
- Bardoxolone methyl, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Blood draw
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Pulmonary Arterial Hypertension, Obstructive Sleep Apnea
- Interventions
- Not listed
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- PAH
- Interventions
- TransCon PEG treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo, Sildenafil
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Providence, Rhode Island
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Prostacyclin Receptor Agonist
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Systemic Sclerosis-Associated PAH
- Interventions
- Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
- Biological · Other · Diagnostic Test + 1 more
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 17
- States / cities
- Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- DHEA tablet, Placebo
- Drug · Other
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Full Term Infants, Environmental Exposures, Adiposity
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 1 Hour to 72 Hours
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ESR-specific PET scan
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 13 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sildenafil citrate
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
- Conditions
- Phenylketonuria, Behavior and Behavior Mechanisms, PAH Gene Expression
- Interventions
- sapropterin dihydrochloride
- Drug
- Lead sponsor
- Tulane University School of Medicine
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
- Interventions
- Tamoxifen, Placebo Oral Tablet
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
- Interventions
- Ralinepag
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Iloprost PD-6, Iloprost PD-15
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Environmental Exposure
- Interventions
- [14C]-benzo[a]pyrene, Brussels sprouts before 50 ng dose, DIM supplement before 50 ng dose
- Drug
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon